acetaminophen has been researched along with Budd-Chiari Syndrome in 4 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Budd-Chiari Syndrome: A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.
Excerpt | Relevance | Reference |
---|---|---|
" In Europe and North America a large proportion of cases are due to acetaminophen and to idiosyncratic drug reactions, whereas reports from emerging countries in Asia and Africa feature viral illnesses, particularly hepatitis B and E." | 4.84 | Etiologies of acute liver failure. ( Lee, WM, 2008) |
"To determine the clinical characteristics of patients with acute liver failure of indeterminate cause and their long-term outcome in comparison with patients with acute liver failure of obvious aetiology (acetaminophen and mushroom poisoning, Budd-Chiari syndrome, acute viral hepatitis) and other controls (idiosyncratic drug reactions, autoimmune hepatitis and Wilson's disease)." | 3.74 | Long-term follow-up of patients with acute liver failure of indeterminate aetiology. ( Bergquist, A; Björnsson, E; Kalaitzakis, E; Wei, G, 2008) |
"The most common causes of ALF were indeterminate liver failure (21%), acute hepatitis B (18%), acetaminophen ingestion (16%), and Budd-Chiari syndrome (9%)." | 3.74 | Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. ( Bahr, MJ; Hadem, J; Klempnauer, J; Manns, MP; Rifai, K; Schneider, AS; Stiefel, P; Tillmann, HL; Wedemeyer, H, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zabron, A | 1 |
Quaglia, A | 1 |
Fatourou, E | 1 |
Peddu, P | 1 |
Lewis, D | 1 |
Heneghan, M | 1 |
Willars, C | 1 |
Auzinger, G | 1 |
Heaton, N | 1 |
Wendon, J | 1 |
Kane, P | 1 |
Karani, J | 1 |
Bernal, W | 1 |
Wei, G | 1 |
Kalaitzakis, E | 1 |
Bergquist, A | 1 |
Björnsson, E | 1 |
Hadem, J | 1 |
Stiefel, P | 1 |
Bahr, MJ | 1 |
Tillmann, HL | 1 |
Rifai, K | 1 |
Klempnauer, J | 1 |
Wedemeyer, H | 1 |
Manns, MP | 1 |
Schneider, AS | 1 |
Lee, WM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
Intervention | Percent Change (Mean) |
---|---|
Maximum Dose Level 3.33 g/24h | 41.2 |
Maximum Dose Level 6.65 g/24h | 16.6 |
Maximum Dose Level 10 g/24h | 41.8 |
Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
Intervention | micrograms per millileter (Mean) |
---|---|
Maximum Dose Level 3.33 g/24h | 65.6 |
Maximum Dose Level 6.65 g/24h | 32.2 |
Maximum Dose Level 10 g/24h | 33.4 |
Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
Intervention | units on a scale (Mean) |
---|---|
Maximum Dose Level 3.33 g/24h | 23.8 |
Maximum Dose Level 6.65 g/24h | 24.0 |
Maximum Dose Level 10 g/24h | 24.0 |
Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
Intervention | units on a scale (Mean) |
---|---|
Maximum Dose Level 3.33 g/24h | 2.4 |
Maximum Dose Level 6.65 g/24h | 3.2 |
Maximum Dose Level 10 g/24h | 1.6 |
Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
Intervention | Participants (Count of Participants) |
---|---|
Maximum Dose Level 3.33 g/24h | 0 |
Maximum Dose Level 6.65 g/24h | 0 |
Maximum Dose Level 10 g/24h | 0 |
Maximum Dose Level 20g/24h | 0 |
1 review available for acetaminophen and Budd-Chiari Syndrome
Article | Year |
---|---|
Etiologies of acute liver failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Drug-Related Side Effects and Adverse | 2008 |
3 other studies available for acetaminophen and Budd-Chiari Syndrome
Article | Year |
---|---|
Clinical and prognostic associations of liver volume determined by computed tomography in acute liver failure.
Topics: Acetaminophen; Adult; Budd-Chiari Syndrome; Decision Support Techniques; Disease Progression; Female | 2018 |
Long-term follow-up of patients with acute liver failure of indeterminate aetiology.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Disease Progression; Female; F | 2008 |
Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Bilirubin; Biomarkers; Budd-Chiari | 2008 |